Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

  1. Berenguer-Ruiz, S.
  2. Aparicio-Domínguez, M.
  3. Herranz-Pinto, P.
  4. Ruíz-Villaverde, R.
  5. López-Ferrer, A.
  6. Santos-Juanes, J.
  7. Rodríguez Fernández-Freire, L.
  8. Hospital-Gil, M.
  9. Arias-Santiago, S.
  10. Carretero-Hernández, G.
  11. Mateu-Puchades, A.
  12. Ferran, M.
  13. del Alcázar, E.
  14. Santos-Alarcón, S.
  15. Garcia-Latasa de Aranibar, F.J.
  16. Belinchón-Romero, I.
  17. González-Cantero, Á.
  18. Ruíz-Genao, D.
  19. Eiris-Salvado, N.
  20. Rocamora-Durán, V.
  21. Rivera-Diaz, R.
  22. de la Cueva, P.
  23. Daudén, E.
  24. Salgado-Boquete, L.
  25. Llamas-Velasco, M.
Aldizkaria:
Journal of the European Academy of Dermatology and Venereology

ISSN: 1468-3083 0926-9959

Argitalpen urtea: 2023

Alea: 37

Zenbakia: 12

Orrialdeak: 2517-2525

Mota: Artikulua

DOI: 10.1111/JDV.19468 GOOGLE SCHOLAR

Garapen Iraunkorreko Helburuak